The Molecular Pathology Laboratory at Mount Sinai, through the leadership of Dr. David Zhang, has become nationally recognized for excellence in technology-based research and clinical molecular diagnostics. More than 6,000 medical laboratory tests are performed each year including 1) tests for infectious agents, such as Human Papiloma Virus and Epstein-Barr virus; 2) tests for genetic disorders, such as Factor V Leiden and Factor II (Prothrombin) gene mutation tests that provide fast and accurate tools to aid in the diagnosis and evaluation of patients with suspected thrombophilia; and 3) tumor oncology assays, such as tests for certain lymphocyte gene rearrangement which act as diagnostic markers for certain lymphomas and leukemias. These tests and other molecular diagnostics tests performed at Mount Sinai allow physicians to diagnose, treat and monitor diseases but most importantly, improve the lives of many patients seen at Mount Sinai.
"We are very excited to partner with Roche Diagnostics, a leader in the diagnostics industry," said David Zhang, MD, PhD, director of the Molecular Pathology Laboratory at Mount Sinai. "With the combination of Roche's cutting edge technologies and our expertise in clinical molecular diagnosis, we will be able to offer the most advanced diagnostic testing to Mount Sinai clinicians to assist with diagnosis, prescription and prognosis. The Molecular Pathology Laboratory has always strived for excellence but this distinction raises the bar and the level of our commitment in providing high quality clinical services that support research and patient care."
The Mount Sinai Hospital
The Mount Sinai Hospital is one of the nation's oldest, largest and most-respected voluntary hospitals. Founded in 1852, Mount Sinai today is a 1,171-bed tertiary-care teaching facility that is internationally-acclaimed for excellence in clinical care.